Corpus overview


Overview

MeSH Disease

Chest Pain (5)

Dyspnea (4)

Fever (2)

Fatigue (2)

Cough (2)


Human Phenotype

Chest pain (5)

Cough (3)

Fever (2)

Fatigue (2)

Pneumonia (2)


Transmission

Seroprevalence
    displaying 1 - 5 records in total 5
    records per page




    The Prevalence SERO and Clinical Significance of Presymptomatic COVID-19 Patients: How We Can be One Step Ahead in Mitigating a Deadly Pandemic

    Authors: Juen Kiem Tan; Dalleen Leong; Hemalatha Munusamy; Nor Hazwani Zenol Ariffin; Najma Kori; Rozita Hod; Petrick Periyasamy

    doi:10.21203/rs.3.rs-60558/v1 Date: 2020-08-16 Source: ResearchSquare

    Presymptomatic COVID-19 patients have been identified as a major stumbling block in efforts to break the chain of transmission TRANS. Studies on temporal dynamics of its shedding suggests it peaks 1-2 days prior to any symptom onset TRANS. Therefore, a large proportion of patients are actively spreading the disease TRANS unknowingly whilst undetected. However, lengthy lockdowns and isolation leads to a host of socioeconomic issues and are impractical. Conversely, there exists no study describing this group and their clinical significance despite their key role in disease transmission TRANS. As a result, we devised a study to look at the prevalence SERO of presymptomatic patients with COVID-19 and subsequently, identify early indicators of infection MESHD through demographic information, biochemical and radiological abnormalities which would allow early diagnosis and isolation. In addition, we will look into the clinical significance of this group and their outcome; if it differs from asymptomatic TRANS or symptomatic patients. Our analysis shows a higher proportion of presymptomatic patients with atypical symptoms like chest pain HP chest pain MESHD while symptomatic patients commonly present with respiratory symptoms like cough HP cough MESHD and shortness of breath MESHD. Besides that, there were more females TRANS presenting as presymptomatic patients and receiving treatment compared to males TRANS and this was found to be statistically significant. Otherwise, we were not able to identify other statistically significant markers suggesting a patient is presymptomatic. As we have little means of identifying these silent spreaders, it highlights further the importance of general measures implemented to stop COVID-19 transmission TRANS like social distancing, face mask, and widespread testing.

    Pericarditis HP Pericarditis MESHD and myocarditis HP myocarditis MESHD long after SARS-CoV-2 infection MESHD: a cross-sectional descriptive study in health-care workers

    Authors: Rocio Eiros; Manuel Barreiro-Perez; Ana Martin-Garcia; Julia Almeida; Eduardo Villacorta; Alba Perez-Pons; Soraya Merchan; Alba Torres-Valle; Clara Sanchez-Pablo; David Gonzalez-Calle; Oihane Perez-Escurza; Ines Toranzo; Elena Diaz-Pelaez; Blanca Fuentes-Herrero; Laura Macias-Alvarez; Guillermo Oliva-Ariza; Quentin Lecrevisse; Rafael Fluxa; Jose L Bravo-Grandez; Alberto Orfao; Pedro L Sanchez

    doi:10.1101/2020.07.12.20151316 Date: 2020-07-14 Source: medRxiv

    Background: Cardiac sequelae of past SARS-CoV-2 infection MESHD are still poorly documented. We conducted a cross-sectional study in health-care workers to report evidence of pericarditis HP pericarditis MESHD and myocarditis HP myocarditis MESHD after SARS-CoV-2 infection MESHD. Methods We studied 139 health-care workers with confirmed past SARS-CoV-2 infection MESHD (103 diagnosed by RT-PCR and 36 by serology). Participants underwent clinical assessment, electrocardiography, laboratory tests including immune cell profiling and cardiac magnetic resonance (CMR) imaging. Pericarditis HP Pericarditis MESHD was diagnosed when classical criteria were present, and the diagnosis of myocarditis HP myocarditis MESHD was based on the updated CMR Lake-Louise-Criteria. Results: Median age TRANS was 52 years (IQR 41-57), 100 (72%) were women, and 23 (16%) were previously hospitalized for Covid-19 pneumonia HP pneumonia MESHD. At examination (10.4 [9.3-11.0] weeks after infection-like symptoms), all participants presented hemodynamic stability. Chest pain HP Chest pain MESHD, dyspnoea MESHD or palpitations HP were observed in 58 (42%) participants; electrocardiographic abnormalities in 69 (50%); NT-pro-BNP was elevated in 11 (8%); troponin in 1 (1%); and CMR abnormalities MESHD in 104 (75%). Isolated pericarditis HP pericarditis MESHD was diagnosed in 4 (3%) participants, myopericarditis in 15 (11%) and isolated myocarditis HP myocarditis MESHD in 36 (26%). Participants diagnosed by RT-PCR were more likely to still present symptoms than participants diagnosed by serology (73 [71%] vs 18 [50%]; p=0.027); nonetheless, the prevalence SERO of pericarditis HP pericarditis MESHD or myocarditis HP myocarditis MESHD was high in both groups (44 [43%] vs 11 [31%]; p=0.238). Most participants (101 [73%]) showed altered immune cell counts in blood SERO, particularly decreased eosinophil (37 [27%]; p<0.001) and increased CD4-CD8-/loT alpha beta-cell numbers (24 [17%]; p<0.001). Pericarditis HP Pericarditis MESHD was associated with elevated CD4-CD8-/loT alpha beta-cell numbers (p=0.011), while participants diagnosed with myopericarditis or myocarditis MESHD myocarditis HP had lower (p<0.05) plasmacytoid dendritic cell, NK-cell and plasma SERO cell counts and lower anti-SARS-CoV-2- IgG antibody SERO levels (p=0.027). Conclusions: Pericarditis HP Pericarditis MESHD and myocarditis HP myocarditis MESHD with clinical stability are frequent long after SARS-CoV-2 infection MESHD, even in presently asymptomatic TRANS subjects. These observations will probably apply to the general population infected and may indicate that cardiac sequelae might occur late in association with an altered (delayed) innate and adaptative immune response.

    SARS-CoV-2 Serology Results in the First COVID-19 Case in California: A Case Report and Recommendations for Serology Testing and Interpretation

    Authors: Richard B. Lanman, MD; Todd H. Lanman

    doi:10.21203/rs.3.rs-35358/v1 Date: 2020-06-12 Source: ResearchSquare

    Background: As countries in COVID-19 pandemic lockdown begin relaxation of shelter-in-place mitigation strategies, the role of serology testing escalates in importance. However, there are no clear guidelines as to when to use qualitative rapid diagnostic serology tests (RDTs) vs. SARS-CoV-2 viral RNA load (PCR) tests as an aid in acute diagnosis of patients presenting with flu-like symptoms, nor how to interpret serology test results in asymptomatic TRANS individuals or those with atypical COVID-19 symptomatology. Here we describe, in the context of the likely first case of COVID-19 in California, with an atypical presentation and not tested acutely, who nearly 3 months later was found to be IgM- and IgG+ positive for SARS-CoV-2 antibodies SERO, highlighting the role of RDT- based serology testing SERO and interpretation in retrospective diagnosis.Case Presentation: A 62-year-old male TRANS practicing neurosurgeon had onset of flu-like symptoms on January 20 with fatigue HP fatigue MESHD, slight cough HP only on deep inspiration, intermittent pleuritic chest pain MESHD chest pain HP unrelated to exertion, dyspnea HP dyspnea MESHD, and night sweats HP but without fever HP fever MESHD, sore throat or rhinorrhea HP rhinorrhea MESHD. He had recently traveled TRANS abroad but not to China. CT scan revealed right lower lobe infiltrate and effusion. Because of atypical symptoms, and low prevalence SERO of COVID-19 in January, community acquired pneumonia HP pneumonia MESHD was diagnosed and one week of doxycycline was prescribed without relief, followed by a second week of azithromycin with symptom remission. Three months later the physician-patient (author THL), tested positive for SARS-CoV-2 antibodies SERO by a serology point-of-care rapid diagnostic test (RDT).Conclusions: Serology testing may be an aid in acute diagnosis of COVID-19, especially in patients with atypical presentations, as well as in assessment of asymptomatic TRANS higher-risk persons such as healthcare workers for prior infection MESHD. Recommendations for serology testing and interpretation are explicated.

    Sociodemographic profile, clinical characteristics, anxiety HP anxiety MESHD, and depression MESHD of 74 patients infected with COVID-19: first report from Bangladesh

    Authors: Dr. Mohammad Jahid Hasan; Dr. Md. Abdullah Saeed Khan; Dr. Monjur Rahman; Dr. Md. Shahnoor Islam; Dr Sourav Debnath; Dr. Jannatul Fardous,; Professor Dr. Mohammad Robed Amin

    doi:10.21203/rs.3.rs-32517/v1 Date: 2020-05-30 Source: ResearchSquare

    Background: The pandemic of Corona Virus Disease MESHD 2019 (COVID-19) has cost a large number of lives and is causing substantial mental stress among people. We conducted a study to identify the sociodemographic and clinical characteristics and prevalence SERO of anxiety HP anxiety MESHD and depression MESHD among confirmed COVID-19 cases in Bangladesh.Methods: An online cross-sectional survey using a preformed questionnaire adapted in Google form was conducted for data collection. The form was shared along with a brief introduction and rationale via Facebook, Twitter, Facebook Messenger, Viber, and What’s App. Formal ethical clearance was taken from the Biomedical Research Foundation, Bangladesh. Informed consent was ensured before participation.Results: Seventy-four patients with COVID-19 who had an average age TRANS of 42.59±14.43 years with male TRANS predominance (77%) were included. A total of 29.7% were doing health-care related jobs, and 14.9% lost their jobs due to COVID-19. Patients had a median income of BDT 30000. Of all, 87.8% of patients were symptomatic and presented with fever HP fever MESHD (77%), cough HP (58.8%), breathlessness (24.3%), myalgia HP myalgia MESHD (24.3%), sore throat (21.6%), fatigue HP fatigue MESHD (17.6%), nausea and/or vomiting HP nausea and/or vomiting MESHD (12.2%), headache HP headache MESHD (12.2%), runny nose (9.5%), chest pain HP chest pain MESHD (9.5%), diarrhea HP diarrhea MESHD (8.1%), ARDS (2.7%), stuffy nose (2.7%), conjunctivitis HP conjunctivitis MESHD (1.4%) and oral ulcer HP oral ulcer MESHD (1.4%). Overall, the prevalence SERO of anxiety HP anxiety MESHD and depression was 60% and 52.9%, respectively. Among the participants, 11.4% had only anxiety HP anxiety MESHD, 4.3% had only depression MESHD and 48.6% had both.Conclusion: Patients were mostly middle aged TRANS, male TRANS and healthy workers. Typical presentations were fever HP fever MESHD and cough HP cough MESHD. Nearly two-thirds of the patients had either or both anxiety HP anxiety MESHD and depression.

    Measuring COVID-19 and Influenza in the Real World via Person-Generated Health Data

    Authors: Nikki Marinsek; Allison Shapiro; Ieuan Clay; Ben Bradshaw; Ernesto Ramirez; Jae Min; Andrew Trister; Yuedong Wang; Tim Althoff; Luca Foschini

    doi:10.1101/2020.05.28.20115964 Date: 2020-05-30 Source: medRxiv

    Background: Since the beginning of the COVID-19 pandemic data from smartphones and connected sensors has been used to learn about symptoms presentation and management outside the clinic walls. However, reports on the validity of such data are still sparse, especially when it comes to symptom progression and relevance of wearable sensors. Objective: To understand the relevance of Person-GeneratedHealth Data ( PGHD MESHD) as a means for early detection, monitoring and management of COVID-19 in everyday life. This includes quantifying prevalence SERO and progression of symptoms from self-reports as well as changes in activity and physiological parameters continuously measured from wearable sensors, and contextualizing findings for COVID-19 patients with those from cohorts of flu patients. Design, Setting, and Participants: Retrospective digital cohort study of individuals with a self-reported positive SARS-CoV-2 or influenza test followed over the period 2019-12-02 to2020-04-27. Three cohorts were derived: Patients who self-reported being diagnosed with flu prior to the SARS-CoV-2 pandemic (N=6270, of which 1226 also contributed sensorPGHD); Patients who reported being diagnosed with flu during the SARS-CoV-2 pandemic (N=426, of which 85 also shared sensor PGHD MESHD); and patients who reported being diagnosed withCOVID-19 (N=230, of which sensor PGHD MESHD was available for 41).The cohorts were derived from a large-scale digital participatory surveillance study designed to track Influenza-like Illness(ILI) incidence and burden over time. Exposures: Self-reported demographic data, comorbidities, and symptoms experienced during a diagnosed ILI episode, including SARS-CoV-2.Physiological and behavioral parameters measured daily from commercial wearable sensors, includingResting Heart Rate (RHR), total step count, and nightly sleep hours. Main Outcomes and Measures: We investigated the percent- age TRANS of individuals experiencing symptoms of a given type (e.g. shortness of breath MESHD) across demographic groups and over time. We examined illness duration, and care seeking behavior, and how RHR, step count, and nightly sleep hours deviated from expected behavior on healthy days over the course of the infection episode. Results: Self-reported symptoms of COVID-19 present differently from flu. COVID-19 cases tended to last longer than flu(median of 12 vs. 9 days), are uniquely characterized by chest pain HP chest pain MESHD/pressure, shortness of breath MESHD, and anosmia HP anosmia MESHD. The fraction of elevated RHR measurements collected daily from commercial wearable devices rise significantly in the 2 days surrounding ILI symptoms onset TRANS, but does not appear to do so in a way specific to COVID-19. Steps lost due to COVID-19 persists for longer. Conclusion and Relevance: PGHD MESHD can be a valid source of longitudinal real world data to detect and monitor COVID-19-related symptoms and behaviors at population scale. PGHD MESHD may provide continuous, near realtime feedback to intervention effectiveness that otherwise requires waiting for symptoms to develop into contacts with the healthcare system. It has also the potential to increase pre-test probability of other downstream diagnostics. To effectively leverage PGHD MESHD for participatory surveillance it is crucial to invest in the creation of trusted, long-term communication channels with individuals through whichdata can be efficiently collected, consented, and contextualized,while protecting the privacy of individuals and ultimately facilitating the transition in and out of care.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.